Pomerantz LLP is investigating claims on behalf of investors in The Chemours Company, which trades on the New York Stock Exchange under CC, over whether the company and certain officers or directors engaged in securities fraud or other unlawful business practices. Chemours cut its 2026 adjusted EBITDA guidance to $775 million-$825 million from $800 million-$900 million previously. Management said initial channel fill led aftermarket customers to build additional inventory, leaving the channel oversupplied heading into 2026, and estimated that about $65 million in aftermarket sales from the second and third quarters should likely have been allocated to the current year on a like-for-like basis. Chemours shares fell $3.34, or 18.63%, to $14.59 on August 10, 2026. The release also reports that AECOM shares fell $6.25, or 8.53%, to $67.05 on August 11 after the company posted weaker-than-expected third-quarter 2026 results, including a $337 million pre-tax loss tied to a delayed construction management project. Investors are advised to contact Danielle Peyton at Pomerantz. The firm says it has recovered numerous multimillion-dollar damages awards for class members, while noting that prior results do not guarantee similar outcomes.